Erinacerin B
Erinacerin B is an isoindolinone skeleton compound. Erinacerin B is present in the mycelia and fruiting bodies of Hericium erinaceus. Erinacerin B inhibits NF-κB (p65 subunit) and AP-1 (c-Jun subunit). Erinacerin B inhibits LPS-induced nitric oxide and Prostaglandin E2 (HY-101952) production. Erinacerin B attenuates neuroinflammation. Erinacerin B is used in research on neurodegenerative and inflammatory diseases.
For research use only. We do not sell to patients.
- CAS No.: 870193-55-8
- Formula: C19H24O5
- Molecular Weight:332.40
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Description
IC50 & Target
[1]|
Fungal Metabolite |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| RAW264.7 | IC50 |
67.36 μM
|
Inhibition of nitric oxide production in LPS-stimulated RAW264.7 macrophage cells pre-treated for 30 mins followed by incubation with LPS for 24 hrs measured by Griess reagent.
Inhibition of nitric oxide production in LPS-stimulated RAW264.7 macrophage cells pre-treated for 30 mins followed by incubation with LPS for 24 hrs measured by Griess reagent.
|
25090632 |
| RAW264.7 | IC50 |
60.10 μM
|
Inhibition of prostaglandin E2 production in LPS-stimulated RAW264.7 macrophage cells pre-treated for 30 mins followed by incubation with LPS for 24 hrs measured by Griess reagent.
Inhibition of prostaglandin E2 production in LPS-stimulated RAW264.7 macrophage cells pre-treated for 30 mins followed by incubation with LPS for 24 hrs measured by Griess reagent.
|
25090632 |
In Vitro
Erinacerin B (48 h) shows weak growth inhibitory activity against T-47D and MDA-MB-231 cell lines[1].
Erinacerin B (1-10 μg/mL; 3 days) shows no cytotoxicity against HUVEC at concentrations up to 10 μg/mL[2].
Erinacerin B (1-10 μg/mL; 3 days) exhibits no cytotoxicity against HDF at concentrations up to 10 μg/mL[2].
Erinacerin B (1-10 μg/mL; 3 days) does not inhibit cellular senescence in HDFs[2].
Erinacerin B (25-100 μM; 24 h) inhibits LPS-induced NO and PGE2 production in RAW264.7 macrophages in a concentration-dependent manner, with IC50 values of 67.36 μM and 60.10 μM, respectively[4].
Erinacerin B (100 μM; 30-60 min) inhibits LPS-induced activation of NF-κB and AP-1 in RAW264.7 macrophages by reducing the phosphorylation of p65 and c-Jun[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:HUVECs
-
Concentration:1, 10 μg/mL
-
Incubation Time:3 days
-
Result:Did not show cytotoxicity at 10 μg/mL.
-
Cell Line:HDFs
-
Concentration:1, 10 μg/mL
-
Incubation Time:3 days
-
Result:Did not show cytotoxicity at 10 μg/mL.
-
Cell Line:RAW264.7
-
Concentration:100 μM
-
Incubation Time:30 min and 60 min
-
Result:Blocked the phosphorylation of NF-κB and AP-1 in a time-dependent manner.
Significantly reduced the abundance of LPS-induced phospho-c-Jun at 30 min.
Significantly reduced the abundance of LPS-induced phospho-p65 at 60 min.
Chemical Information
-
CAS No. 870193-55-8
-
Molecular Weight 332.40
-
Formula C19H24O5
-
SMILES
OC1=C2C(=CC(OC)=C1C/C=C(/C[C@@H](C=C(C)C)O)\C)C(=O)OC2
-
Structure Classification
-
Initial Source
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
-
Research Protocol for Neurological Diseases
PINK1/Parkin-mediated mitophagy pathway is a mitochondrial quality-control signaling axis in which mitochondrial depolarization stabilizes PINK1 on damaged mitochondria, activates Parkin recruitment and E3 ubiquitin ligase activity, promotes ubiquitination of outer mitochondrial membrane proteins, recruits selective autophagy adaptors, and drives lysosomal degradation of damaged mitochondria. In neurological disease research, this pathway is experimentally important because neurons, especially dopaminergic neurons, are highly dependent on mitochondrial integrity, and defective mitochondrial turnover can lead to mitochondrial dysfunction, oxidative stress, impaired neuronal survival, α-synuclein accumulation, and neuroinflammatory damage-associated signals. The genetic disease link is strongest in Parkinson’s disease because mutations in PRKN/parkin cause autosomal recessive juvenile parkinsonism, mutations in PINK1 cause hereditary early-onset Parkinson’s disease, and Drosophila studie
Purity & Documentation
References
[2]. Noh HJ, et al. Chemical constituents of Hericium erinaceum associated with the inhibitory activity against cellular senescence in human umbilical vascular endothelial cells. Journal of enzyme inhibition and medicinal chemistry. 2015 Dec;30(6):934-40. [Content Brief]
[3]. Lin JY, et al. Discovery of a new compound, erinacerin W, from the mycelia of Hericium erinaceus, with immunomodulatory and neuroprotective effects. Molecules. 2024 Feb 9;29(4):812. [Content Brief]
[4]. Noh HJ, et al. Benzyl alcohol derivatives from the mushroom Hericium erinaceum attenuate LPS-stimulated inflammatory response through the regulation of NF-κB and AP-1 activity. Immunopharmacology and immunotoxicology. 2014 Oct;36(5):349-54. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Erinacerin B Related Classifications
HY-N21647 Related Classifications
Powered by Bioz